If you would like to ask our webinar guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund a question please submit them here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksREDX.L Regulatory News (REDX)

  • There is currently no data for REDX

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Form 8 (OPD) - Jounce Therapeutics, Inc

9 Mar 2023 11:22

RNS Number : 4654S
Redx Pharma plc
09 March 2023
 

FORM 8 (OPD)

 

PUBLIC OPENING POSITION DISCLOSURE BY A PARTY TO AN OFFER

Rules 8.1 and 8.2 of the Takeover Code (the "Code")

 

1. KEY INFORMATION

 

(a) Full name of discloser:

Redx Pharma plc

(b) Owner or controller of interests and short positions disclosed, if different from 1(a):

The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.

N/A

 

 

(c) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

Jounce Therapeutics, Inc ("Jounce")

(d) Is the discloser the offeror or the offeree?

Offeree

(e) Date position held:

The latest practicable date prior to the disclosure

9 March 2023

(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?

If it is a cash offer or possible cash offer, state "N/A"

Yes - Redx Pharma plc

 

 

2. POSITIONS OF THE PARTY TO THE OFFER MAKING THE DISCLOSURE

 

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

 

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates

 

Class of relevant security:

 

Jounce common shares of $0.001 par value per share ("Shares")

 

 

Interests

Short positions

Number

%

Number

%

(1) Relevant securities owned and/or controlled:

0

-

0

-

(2) Cash-settled derivatives:

 

0

-

0

-

(3) Stock-settled derivatives (including options) and agreements to purchase/sell:

0

-

0

-

TOTAL:

0

-

0

-

 

All interests and all short positions should be disclosed.

 

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

 

Details of any securities borrowing and lending positions or financial collateral arrangements should be disclosed on a Supplemental Form 8 (SBL).

 

(b) Rights to subscribe for new securities

 

Class of relevant security in relation to which subscription right exists:

N/A

Details, including nature of the rights concerned and relevant percentages:

N/A

 

 

3. POSITIONS OF PERSONS ACTING IN CONCERT WITH THE PARTY TO THE OFFER MAKING THE DISCLOSURE

 

Details of any interests, short positions and rights to subscribe (including directors' and other employee options) of any person acting in concert with the party to the offer making the disclosure:

 

Registered holder

Class

Number of Shares

Percentage shareholding (%)

Sidley Austin Master Pension Trust ("SAMP Trust")

Jounce common shares of $0.001 par value per share

2,968

0.00569234%

SA Investment Partnership IV LLC ("SAIP IV")

Jounce common shares of $0.001 par value per share

1,978

0.00379361%

 

The SAMP Trust is a benefit plan trust that holds certain assets of Sidley Austin LLP's U.S.-based retirement plans. SAIP IV is an employees' securities company whose members are current or former partners or senior staff members of Sidley Austin LLP (or trusts formed by such persons).

 

Sidley Austin LLP is acting as legal adviser to RedCo II Master Fund, L.P. and RM Special Holdings 3, LLC.

 

 

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

 

Details of any securities borrowing and lending positions or financial collateral arrangements should be disclosed on a Supplemental Form 8 (SBL).

 

4. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the party to the offer making the disclosure or any person acting in concert with it:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the party to the offer making the disclosure, or any person acting in concert with it, and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

(c) Attachments

 

Are any Supplemental Forms attached?

 

Supplemental Form 8 (Open Positions)

No

Supplemental Form 8 (SBL)

No

 

 

Date of disclosure:

9 March 2023

Contact name:

Claire Solk, Group Company Secretary

Telephone number:

+44(0)1625 469900

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

 

The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
FEEFLFFLVIIAIIV
Date   Source Headline
27th Oct 20227:00 amRNSRedx to Present Poster at ASN Kidney Week
11th Oct 20227:00 amRNSFirst Patient Dosed in Phase 2a Trial for RXC007
3rd Oct 20227:00 amRNSRedx Presents RXC007 Preclinical and Phase 1 Data
29th Sep 20227:41 amRNSRedx to Present Poster on RXC007 at ICLAF
6th Sep 20227:00 amRNSTR-1: Notification of major holdings
31st Aug 20227:00 amRNSRedx to Present at the ERS International Congress
5th Aug 202211:52 amRNSCompletion of Placing and Director/PDMR Dealings
3rd Aug 20221:43 pmRNSProposed Secondary Placing of Shares via ABB
26th Jul 20221:47 pmRNSExercise of Options, PDMR Dealing and TVR
11th Jul 20227:00 amRNSRedx to Present at Virtual Investor Forum
27th Jun 20227:00 amRNSEncouraging Data on Porcupine and ROCK Inhibitors
23rd Jun 20227:00 amRNSInterim Results for the Six Months Ended 31 March
20th Jun 20227:00 amRNSRedx to Present at the ECM Congress
16th Jun 20227:00 amRNSNotice of Interim Results
15th Jun 20227:00 amRNSPan-RAF Inhibitor to Enter Clinical Development
9th Jun 20224:34 pmRNSTR-1: Notification of major holdings
8th Jun 20221:28 pmRNSTR-1: Notification of major holdings
7th Jun 20228:11 amRNSAdmission of Placing Shares
6th Jun 202211:56 amRNSResults of General Meeting
30th May 20227:00 amRNSRedx Presents Poster on RXC004 at ASCO
25th May 20227:00 amRNSRedx to Present at Jefferies Healthcare Conference
20th May 20227:00 amRNSNew Grant of Options
19th May 20222:34 pmRNSNew Grant of Options
19th May 202212:14 pmRNSResult of Accelerated Bookbuild
18th May 20226:28 pmRNSLaunch of Placing via Accelerated Bookbuild
27th Apr 20223:00 pmRNSRedx to Present at ASCO
8th Apr 20226:00 pmRNSRedx Presents Encouraging RXC004 Preclinical Data
5th Apr 20227:00 amRNSCollaboration with the Garvan Institute
30th Mar 20227:00 amRNSNomination of Clinical Development Candidate
24th Mar 20227:00 amRNSRedx to Present at the AACR Annual Meeting
10th Mar 20227:00 amRNSRedx Presents Encouraging Phase 1 Data for RXC007
9th Mar 20227:00 amRNSBoard Committee Changes
8th Mar 202212:30 pmRNSResult of AGM
2nd Mar 20227:00 amRNSRedx to Present at Cowen Health Care Conference
28th Feb 20227:00 amRNSRedx to Present at ILD Summit 2022
11th Feb 20224:43 pmRNSNotice of AGM
28th Jan 20227:00 amRNSNew Grant of Share Options
27th Jan 20227:01 amRNSAppointment of Non-Executive Director
27th Jan 20227:00 amRNSFinal Audited Results and Operational Update
25th Jan 202212:00 pmRNSNotice of Preliminary Results
23rd Dec 20217:00 amRNSRedx to Receive Milestone Payment of $9m from AZ
9th Dec 20214:41 pmRNSSecond Price Monitoring Extn
9th Dec 20214:36 pmRNSPrice Monitoring Extension
9th Dec 20212:06 pmRNSSecond Price Monitoring Extn
9th Dec 20212:00 pmRNSPrice Monitoring Extension
9th Dec 20217:00 amRNSRedx to receive milestone of $10m from Jazz
6th Dec 20217:00 amRNSRedx and Caris Life Sciences Announce Partnership
30th Nov 20217:00 amRNSRedx to Participate at Piper Sandler Conference
17th Nov 20217:00 amRNSRedx to Present at Jefferies London Conference
15th Nov 20217:00 amRNSFirst Patient Dosed in Phase 2 Trial of RXC004

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.